{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T05:03:11Z","timestamp":1785560591536,"version":"3.56.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02895-y","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:26:04Z","timestamp":1752776764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Potential therapeutic targets in chronic myeloid leukemia"],"prefix":"10.1007","volume":"42","author":[{"given":"Manvi","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2395-6086","authenticated-orcid":false,"given":"Malkhey","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"2895_CR1","unstructured":"Eden RE, Coviello JM. Chronic Myelogenous Leukemia. In: StatPearls[Internet]. StatPearls Publishing. 2023.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531459\/"},{"issue":"6","key":"2895_CR2","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia. 2015;29(6):1336\u201343. https:\/\/doi.org\/10.1038\/leu.2015.73.","journal-title":"Leukemia"},{"issue":"12","key":"2895_CR3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1691\/ph.2021.1744","volume":"76","author":"R Shi","year":"2021","unstructured":"Shi R, Liu X. CD44: a potential therapeutic target in chronic myeloid leukemia. Pharm - Int J Pharm Sci. 2021;76(12):574\u20138. https:\/\/doi.org\/10.1691\/ph.2021.1744.","journal-title":"Pharm - Int J Pharm Sci"},{"issue":"12","key":"2895_CR4","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1182\/blood-2006-06-032490","volume":"109","author":"H Modi","year":"2007","unstructured":"Modi H, McDonald T, Chu S, Yee JK, Forman SJ, Bhatia R. Role of BCR\/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood. 2007;109(12):5411\u201321. https:\/\/doi.org\/10.1182\/blood-2006-06-032490.","journal-title":"Blood"},{"issue":"1","key":"2895_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/asheducation-2017.1.115","volume":"2017","author":"R Bhatia","year":"2017","unstructured":"Bhatia R. Novel approaches to therapy in CML. Hematol Am Soc Hematol Educ Program. 2017;2017(1):115\u201320. https:\/\/doi.org\/10.1182\/asheducation-2017.1.115.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"2895_CR6","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","volume":"90","author":"MWN Deininger","year":"1997","unstructured":"Deininger MWN, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL\u2013positive cells. Blood. 1997;90(9):3691\u20138. https:\/\/doi.org\/10.1182\/blood.V90.9.3691.","journal-title":"Blood"},{"key":"2895_CR7","unstructured":"Haider MZ, Anwer F. Genetics, Philadelphia Chromosome. In: StatPearls. StatPearls Publishing. 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560689\/"},{"issue":"9","key":"2895_CR8","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022;97(9):1236\u201356. https:\/\/doi.org\/10.1002\/ajh.26642.","journal-title":"Am J Hematol"},{"key":"2895_CR9","doi-asserted-by":"publisher","DOI":"10.21037\/ncri-2020-006","author":"A Ghazaryan","year":"2020","unstructured":"Ghazaryan A, Goodwin CB, O\u2019Connell RM. A microRNA prevents resistance to targeted therapy in chronic myeloid leukemia. Non-Coding RNA Investig. 2020. https:\/\/doi.org\/10.21037\/ncri-2020-006.","journal-title":"Non-Coding RNA Investig"},{"issue":"9","key":"2895_CR10","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"JP Radich","year":"2018","unstructured":"Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hobbs G. Chronic myeloid leukemia, version 1. 2019, NCCN clinical practice guidelines in oncology. J Nat Compr Cancer Netw. 2018;16(9):1108\u201335. https:\/\/doi.org\/10.6004\/jnccn.2018.0071.","journal-title":"J Nat Compr Cancer Netw"},{"issue":"1","key":"2895_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/asheducation-2018.1.168","volume":"2018","author":"N Shanmuganathan","year":"2018","unstructured":"Shanmuganathan N, Hughes TP. Molecular monitoring in CML: how deep? How often? How should it influence therapy? Hematol Am Soc Hematol Educ Program. 2018;2018(1):168\u201376. https:\/\/doi.org\/10.1182\/asheducation-2018.1.168.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"7","key":"2895_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3238\/arztebl.2010.0114","volume":"107","author":"N Von Bubnoff","year":"2010","unstructured":"Von Bubnoff N, Duyster J. Chronic myelogenous leukemia. DtschArzteblatt Int. 2010;107(7):114\u201321. https:\/\/doi.org\/10.3238\/arztebl.2010.0114.","journal-title":"DtschArzteblatt Int"},{"issue":"10","key":"2895_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1609324.","journal-title":"N Engl J Med"},{"issue":"4","key":"2895_CR14","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/sj.leu.2402068","volume":"15","author":"Y Kawaguchi","year":"2001","unstructured":"Kawaguchi Y, Jinnai I, Nagai K, Yagasaki F, Yakata Y, Matsuo T, Kuriyama K, Tomonaga M. Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells. Leukemia. 2001;15(4):590\u20134. https:\/\/doi.org\/10.1038\/sj.leu.2402068.","journal-title":"Leukemia"},{"issue":"1","key":"2895_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/ejh.14299","volume":"114","author":"C Bucelli","year":"2025","unstructured":"Bucelli C, Capodanno I, Miggiano MC, Cavazzini F, Crescenzi SL, Russo S, Carmosino I, Annunziata M, Sor\u00e0 F, Bonifacio M, Luciano L. Choice of frontline tyrosine-kinase inhibitor and early events in very elderly patients with chronic myeloid leukemia in chronic phase: a \u201cCampus CML\u201d study. Eur J Haematol. 2025;114(1):37\u201344. https:\/\/doi.org\/10.1111\/ejh.14299.","journal-title":"Eur J Haematol"},{"issue":"2","key":"2895_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/2040620712468289","volume":"4","author":"PK Bhamidipati","year":"2013","unstructured":"Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 2013;4(2):103\u201317. https:\/\/doi.org\/10.1177\/2040620712468289.","journal-title":"Ther Adv Hematol"},{"issue":"9","key":"2895_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(11)70201-7.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2895_CR18","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ddr.21266","volume":"76","author":"K Kotagama","year":"2015","unstructured":"Kotagama K, Chang Y, Mangone M. miRNAs as biomarkers in chronic myelogenous leukemia. Drug Dev Res. 2015;76(6):278\u201385. https:\/\/doi.org\/10.1002\/ddr.21266.","journal-title":"Drug Dev Res"},{"issue":"3","key":"2895_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jnccn.2012.0184","volume":"10","author":"J Cortes","year":"2012","unstructured":"Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Nat Compr Cancer Netw. 2012;10(3):1. https:\/\/doi.org\/10.6004\/jnccn.2012.0184.","journal-title":"J Nat Compr Cancer Netw"},{"issue":"8","key":"2895_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1684\/bdc.2011.1408","volume":"98","author":"M Demarquet","year":"2011","unstructured":"Demarquet M, Labussi\u00e8re-Wallet H, Nicolas-Virelizier E, Nicolini FE. A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia. Bull Cancer (Paris). 2011;98(8):859\u201366. https:\/\/doi.org\/10.1684\/bdc.2011.1408.","journal-title":"Bull Cancer (Paris)."},{"issue":"6","key":"2895_CR21","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-021-01260-y","volume":"35","author":"TP Hughes","year":"2021","unstructured":"Hughes TP, Clementino NCD, Fominykh M, Lipton JH, Turkina AG, Moiraghi EB, Nicolini FE, Takahashi N, Sacha T, Kim DW, Fellague-Chebra R. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia. 2021;35(6):1631\u201342. https:\/\/doi.org\/10.1038\/s41375-021-01260-y.","journal-title":"Leukemia"},{"issue":"2","key":"2895_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, Le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440\u201353. https:\/\/doi.org\/10.1038\/s41375-020-01111-2.","journal-title":"Leukemia"},{"issue":"14","key":"2895_CR23","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/bloodadvances.2020003759","volume":"5","author":"N Hijiya","year":"2021","unstructured":"Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S. A phase 2 study of nilotinib in pediatric patients with CML: Long-term update on growth retardation and safety. Blood Adv. 2021;5(14):2925\u201334. https:\/\/doi.org\/10.1182\/bloodadvances.2020003759.","journal-title":"Blood Adv"},{"issue":"20","key":"2895_CR24","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1182\/bloodadvances.2024012655","volume":"8","author":"I Matsumura","year":"2024","unstructured":"Matsumura I, Ohtake S, Atsuta Y, Kurata M, Minami Y, Takahashi N, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y. Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study. Blood Adv. 2024;8(20):5237\u201347. https:\/\/doi.org\/10.1182\/bloodadvances.2024012655.","journal-title":"Blood Adv"},{"issue":"1","key":"2895_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-025-01242-8","volume":"15","author":"L Busque","year":"2025","unstructured":"Busque L, Beaudet M\u00c9, Harnois M, Moussa H, Szuber N, Mollica L, Delage R, Olney H, Laneuville P, Cournoyer G, Chamakhi I. Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study. Blood Cancer J. 2025;15(1):35. https:\/\/doi.org\/10.1038\/s41408-025-01242-8.","journal-title":"Blood Cancer J"},{"issue":"5","key":"2895_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401\u201312. https:\/\/doi.org\/10.1016\/j.ccr.2009.09.028.","journal-title":"Cancer Cell"},{"issue":"3","key":"2895_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41375-024-02159-0","volume":"38","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, Chuah C, DeAngelo DJ, Hochhaus A, Lipton JH, Mauro M. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024;38(3):475\u201381. https:\/\/doi.org\/10.1038\/s41375-024-02159-0.","journal-title":"Leukemia"},{"issue":"10","key":"2895_CR28","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391(10):885\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2400858.","journal-title":"N Engl J Med"},{"issue":"24","key":"2895_CR29","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1902328.","journal-title":"N Engl J Med"},{"issue":"3","key":"2895_CR30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.38.6565.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2895_CR31","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, G\u00f6hring G, Proetel U, Kolb HJ. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096\u2013102. https:\/\/doi.org\/10.1038\/leu.2012.85.","journal-title":"Leukemia"},{"issue":"20","key":"2895_CR32","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Final 5-year study results of dasision: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340. https:\/\/doi.org\/10.1200\/JCO.2015.64.8899.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2895_CR33","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2014","unstructured":"Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353\u201360. https:\/\/doi.org\/10.1182\/blood-2013-06-510396.","journal-title":"Blood"},{"key":"2895_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/annonc\/mdx219","volume":"4","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2017;4:5\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdx219.","journal-title":"Ann Oncol"},{"issue":"4","key":"2895_CR35","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384. https:\/\/doi.org\/10.1038\/s41375-020-0776-2.","journal-title":"Leukemia"},{"issue":"6","key":"2895_CR36","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Breccia M, Saglio G, Garc\u00eda-Guti\u00e9rrez V, R\u00e9a D, Janssen J, Apperley J. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34(6):1495\u2013502. https:\/\/doi.org\/10.1038\/s41375-020-0842-9.","journal-title":"Leukemia"},{"issue":"6","key":"2895_CR37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","volume":"15","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015;15(6):323\u201334. https:\/\/doi.org\/10.1016\/j.clml.2015.03.006.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7647","key":"2895_CR38","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S. The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1. Nature. 2017;543(7647):733\u20137. https:\/\/doi.org\/10.1038\/nature21702.","journal-title":"Nature"},{"key":"2895_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98: 106458. https:\/\/doi.org\/10.1016\/j.leukres.2020.106458.","journal-title":"Leuk Res"},{"issue":"18","key":"2895_CR40","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, Dodd S, Drueckes P, Fabbro D, Gabriel T, Groell JM. Discovery of Asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61(18):8120\u201335. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01040.","journal-title":"J Med Chem"},{"issue":"4","key":"2895_CR41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D. Combining the Allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36(4):431-443.e5. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.004.","journal-title":"Cancer Cell"},{"issue":"S1","key":"2895_CR42","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.5045\/br.2023.2023017","volume":"58","author":"EJ Choi","year":"2023","unstructured":"Choi EJ. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase. Blood Res. 2023;58(S1):S29\u201336. https:\/\/doi.org\/10.5045\/br.2023.2023017.","journal-title":"Blood Res"},{"key":"2895_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14796694.2024.2439178","volume":"1","author":"N Szuber","year":"2025","unstructured":"Szuber N, Machado L, Kim DD. Asciminib versus bosutinib following 2 or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL study. Future Oncol. 2025;1:5\u20136. https:\/\/doi.org\/10.1080\/14796694.2024.2439178.","journal-title":"Future Oncol"},{"issue":"5","key":"2895_CR44","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/cbin.70007","volume":"49","author":"A Cavalleri","year":"2025","unstructured":"Cavalleri A, Xhahysa B, Mutti S, Ferraro RM, Mazzoldi EL, Farina M, Leoni A, Garuffo L, Trenta F, Re F, Radici V. Different in vitro models of chronic myeloid leukemia show different characteristics: biological replicates are not biologically equivalent. Cell Biol Int. 2025;49(5):570\u201386. https:\/\/doi.org\/10.1002\/cbin.70007.","journal-title":"Cell Biol Int"},{"issue":"20","key":"2895_CR45","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.3390\/cancers13205116","volume":"13","author":"T Ono","year":"2021","unstructured":"Ono T. Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase? Cancers. 2021;13(20):5116. https:\/\/doi.org\/10.3390\/cancers13205116.","journal-title":"Cancers"},{"issue":"4","key":"2895_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ. Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393\u2013404. https:\/\/doi.org\/10.1182\/blood-2016-09-739086.","journal-title":"Blood"},{"issue":"5","key":"2895_CR47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/jnci\/djx236","volume":"110","author":"R Mitchell","year":"2018","unstructured":"Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, Hamilton G, Mukhopadhyay A, O\u2019prey J, Hair A, Melo JV. Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition. J Natl Cancer Inst. 2018;110(5):467\u201378. https:\/\/doi.org\/10.1093\/jnci\/djx236.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2895_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-022-00667-9","volume":"12","author":"S Adnan Awad","year":"2022","unstructured":"Adnan Awad S, Br\u00fcck O, Shanmuganathan N, Jarvinen T, L\u00e4hteenm\u00e4ki H, Klievink J, Ibrahim H, Kyt\u00f6l\u00e4 S, Koskenvesa P, Hughes TP, Branford S. Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation. Blood Cancer J. 2022;12(4):69. https:\/\/doi.org\/10.1038\/s41408-022-00667-9.","journal-title":"Blood Cancer J"},{"issue":"13","key":"2895_CR49","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1182\/bloodadvances.2018017772","volume":"2","author":"AS Bouillon","year":"2018","unstructured":"Bouillon AS, Ventura Ferreira MS, Awad SA, Richter J, Hochhaus A, Kunzmann V, Dengler J, Janssen J, Ossenkoppele G, Westerweel PE, Te Boekhorst PA. Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia. Blood Adv. 2018;2(13):1572\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2018017772.","journal-title":"Blood Adv"},{"key":"2895_CR50","doi-asserted-by":"publisher","DOI":"10.4103\/ijh.ijh_89_24","author":"NM Shakri","year":"2025","unstructured":"Shakri NM, Zulkeflee RH, Hassan MN, Salleh S, Shuyuti NA, Ramli M, Husin A, Abdullah AD. A decade-long analysis of 98 chronic myeloid leukemia patients: laboratory data and clinical progress at a single center. Iraqi J Hematol. 2025. https:\/\/doi.org\/10.4103\/ijh.ijh_89_24.","journal-title":"Iraqi J Hematol"},{"issue":"6","key":"2895_CR51","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, M\u00fcller-Tidow C, Bhatia R, Brunton VG, Koschmieder S, Holyoake TL. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501\u201310. https:\/\/doi.org\/10.1182\/blood-2010-12-326843.","journal-title":"Blood"},{"issue":"1","key":"2895_CR52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/01.COT.0001097248.87305.9d","volume":"47","author":"C Nalley","year":"2025","unstructured":"Nalley C, Advanced CML. Patients treated with novel three-drug combination. Oncol Times. 2025;47(1):20\u20131. https:\/\/doi.org\/10.1097\/01.COT.0001097248.87305.9d.","journal-title":"Oncol Times."},{"issue":"15","key":"2895_CR53","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-13-3044","volume":"20","author":"B S\u00e1nchez-S\u00e1nchez","year":"2014","unstructured":"S\u00e1nchez-S\u00e1nchez B, Guti\u00e9rrez-Herrero S, L\u00f3pez-Ruano G, Prieto-Bermejo R, Romo-Gonz\u00e1lez M, Llanillo M, Pandiella A, Guerrero C, Miguel JFS, S\u00e1nchez-Guijo F, del Ca\u00f1izo C, Hern\u00e1ndez-Hern\u00e1ndez A. NADPH oxidases as therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res. 2014;20(15):4014\u201325. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3044.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2895_CR54","doi-asserted-by":"publisher","first-page":"8833","DOI":"10.1038\/s41598-021-86875-y","volume":"11","author":"MA Ismail","year":"2021","unstructured":"Ismail MA, Vezzalini M, Morsi H, Abujaber A, Al Sayab A, Siveen K, Yassin MA, Monne M, Samara M, Cook R, Sorio C, Modjtahedi H, Al-Dewik NI. Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients. Sci Rep. 2021;11(1):8833. https:\/\/doi.org\/10.1038\/s41598-021-86875-y.","journal-title":"Sci Rep"},{"issue":"10","key":"2895_CR55","doi-asserted-by":"publisher","first-page":"9442","DOI":"10.18632\/oncotarget.24253","volume":"9","author":"J Drube","year":"2018","unstructured":"Drube J, Ernst T, Pfirrmann M, Albert BV, Drube S, Reich D, Kresinsky A, Halfter K, Sorio C, Fabisch C, Hochhaus A, B\u00f6hmer FD. PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells. Oncotarget. 2018;9(10):9442\u201355. https:\/\/doi.org\/10.18632\/oncotarget.24253.","journal-title":"Oncotarget"},{"key":"2895_CR56","doi-asserted-by":"publisher","first-page":"107327482211402","DOI":"10.1177\/10732748221140201","volume":"29","author":"MA Ismail","year":"2022","unstructured":"Ismail MA, Sorio C, Al-Dewik N. Protein tyrosine phosphatase receptor gamma as potential therapeutic target for chronic myeloid leukemia patients. Cancer Control. 2022;29:10732748221140200. https:\/\/doi.org\/10.1177\/10732748221140201.","journal-title":"Cancer Control"},{"key":"2895_CR57","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.canlet.2019.11.017","volume":"469","author":"C Grandjenette","year":"2020","unstructured":"Grandjenette C, Schnekenburger M, Gaigneaux A, Gerard D, Christov C, Mazumder A, Dicato M, Diederich M. Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells. Cancer Lett. 2020;469:468\u201380. https:\/\/doi.org\/10.1016\/j.canlet.2019.11.017.","journal-title":"Cancer Lett"},{"issue":"1","key":"2895_CR58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/diseases6010013","volume":"6","author":"HM Al-Kuraishy","year":"2018","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Al-Buhadilly AK. p53 gene (NY-CO-13) levels in patients with chronic myeloid leukemia: the role of imatinib and nilotinib. Diseases. 2018;6(1):13. https:\/\/doi.org\/10.3390\/diseases6010013.","journal-title":"Diseases"},{"issue":"5","key":"2895_CR59","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.3324\/haematol.2019.219261","volume":"105","author":"BZ Carter","year":"2020","unstructured":"Carter BZ, Mak PY, Mu H, Wang X, Tao W, Mak DH, Dettman EJ, Cardone M, Zernovak O, Seki T, Andreeff M. Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem\/progenitor cells in a murine model. Haematologica. 2020;105(5):1274\u201384. https:\/\/doi.org\/10.3324\/haematol.2019.219261.","journal-title":"Haematologica"},{"key":"2895_CR60","doi-asserted-by":"publisher","first-page":"107644","DOI":"10.1016\/j.leukres.2025.107644","volume":"149","author":"MB Fontecha","year":"2025","unstructured":"Fontecha MB, del Rosario Anad\u00f3n M, Lahitou IMM, Weich N, Bengi\u00f3 R, Moiraghi B, Larripa I, Fundia AF. Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia. Leukemia Res. 2025;149:107644. https:\/\/doi.org\/10.1016\/j.leukres.2025.107644.","journal-title":"Leukemia Res"},{"issue":"8","key":"2895_CR61","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/ng.2350","volume":"44","author":"H Zhang","year":"2012","unstructured":"Zhang H, Peng C, Hu Y, Li H, Sheng Z, Chen Y, Sullivan C, Cerny J, Hutchinson L, Higgins A, Miron P, Zhang X, Brehm MA, Li D, Green MR, Li S. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet. 2012;44(8):861\u201371. https:\/\/doi.org\/10.1038\/ng.2350.","journal-title":"Nat Genet"},{"issue":"1","key":"2895_CR62","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4103\/1110-1067.124843","volume":"39","author":"NA Nosair","year":"2014","unstructured":"Nosair NA, Bar ESAE, Taha AM, Gawaly AM. Fas (CD95) expression as a prognostic marker in acute leukemia and blastic transformation phase in chronic myeloid leukemia. Egypt J Haematol. 2014;39(1):25\u201331. https:\/\/doi.org\/10.4103\/1110-1067.124843.","journal-title":"Egypt J Haematol"},{"issue":"5","key":"2895_CR63","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","volume":"8","author":"P Neviani","year":"2005","unstructured":"Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein. Cancer Cell. 2005;8(5):355\u201368. https:\/\/doi.org\/10.1016\/j.ccr.2005.10.015.","journal-title":"Cancer Cell"},{"issue":"1","key":"2895_CR64","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4999\/uhod.214448","volume":"31","author":"OD Akdeniz","year":"2021","unstructured":"Akdeniz OD. Downregulation of Forkhead transcription factor (FOXO3a) contributes to tumorigenesis of acute myeloid leukemia and chronic myeloid leukemia. Int J Hematol Oncol. 2021;31(1):28\u201335. https:\/\/doi.org\/10.4999\/uhod.214448.","journal-title":"Int J Hematol Oncol"},{"issue":"21","key":"2895_CR65","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1182\/blood.V122.21.4905.4905","volume":"122","author":"S Maifrede","year":"2013","unstructured":"Maifrede S, Liebermann D, Hoffman B. Stress response transcription factor Egr-1 As tumor suppressor Of CML. Blood. 2013;122(21):4905. https:\/\/doi.org\/10.1182\/blood.V122.21.4905.4905.","journal-title":"Blood"},{"issue":"11","key":"2895_CR66","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S0145-2126(98)00076-9","volume":"22","author":"B Garicochea","year":"1998","unstructured":"Garicochea B, Giorgi R, Odone VF, Dorlhiac-Llacer PE, Bendit I. Mutational analysis of N-RAS and GAP-related domain of the neurofibromatosis type 1 gene in chronic myelogenous leukemia. Leuk Res. 1998;22(11):1003\u20137. https:\/\/doi.org\/10.1016\/S0145-2126(98)00076-9.","journal-title":"Leuk Res"},{"issue":"2","key":"2895_CR67","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/leu.2012.220","volume":"27","author":"DA Casolari","year":"2013","unstructured":"Casolari DA, Makri M, Yoshida C, Muto A, Igarashi K, Melo JV. Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5. Leukemia. 2013;27(2):409\u201315. https:\/\/doi.org\/10.1038\/leu.2012.220.","journal-title":"Leukemia"},{"issue":"23","key":"2895_CR68","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.3390\/jcm10235606","volume":"10","author":"M Massimino","year":"2021","unstructured":"Massimino M, Vigneri P, Stella S, Tirr\u00f2 E, Pennisi MS, Parrinello LN, Vetro C, Manzella L, Stagno F, Di Raimondo F. Combined inhibition of Bcl2 and Bcr-Abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells. J Clin Med. 2021;10(23):5606. https:\/\/doi.org\/10.3390\/jcm10235606.","journal-title":"J Clin Med"},{"issue":"8","key":"2895_CR69","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","volume":"105","author":"KJ Aichberger","year":"2004","unstructured":"Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C. identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood. 2004;105(8):3303\u201311. https:\/\/doi.org\/10.1182\/blood-2004-02-0749.","journal-title":"Blood"},{"issue":"23","key":"2895_CR70","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1182\/blood-2013-07-516807","volume":"123","author":"K Rothe","year":"2014","unstructured":"Rothe K, Lin H, Lin KBL, Leung A, Wang HM, Malekesmaeili M, Brinkman RR, Forrest DL, Gorski SM, Jiang X. The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem\/progenitor cells. Blood. 2014;123(23):3622\u201334. https:\/\/doi.org\/10.1182\/blood-2013-07-516807.","journal-title":"Blood"},{"key":"2895_CR71","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/15330338211052150","volume":"4","author":"H Dai","year":"2021","unstructured":"Dai H, Wang J, Huang Z, Zhang H, Wang X, Li Q, Feng W. LncRNA OIP5-AS1 promotes the autophagy-related imatinib resistance in chronic myeloid leukemia cells by regulating miR-30e-5p\/ATG12 Axis. Technol Cancer Res Treat. 2021;4:5\u20136. https:\/\/doi.org\/10.1177\/15330338211052150.","journal-title":"Technol Cancer Res Treat"},{"issue":"11","key":"2895_CR72","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/molecules30112294","volume":"30","author":"M Zhang","year":"2025","unstructured":"Zhang M, Wang J, Jiang R, Liu M, Zhang W. Unlocking the potential of perillaldehyde: a novel mechanism for chronic myeloid leukemia by targeting HSP70. Molecules. 2025;30(11):4\u20136. https:\/\/doi.org\/10.3390\/molecules30112294.","journal-title":"Molecules"},{"key":"2895_CR73","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cbi.2018.06.006","volume":"291","author":"PH Chen","year":"2018","unstructured":"Chen PH, Liu AJ, Ho KH, Chiu YT, Lin ZH, Lee YT, Shih CM, Chen KC. microRNA-199a\/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells. Chem Biol Interact. 2018;291:144\u201351. https:\/\/doi.org\/10.1016\/j.cbi.2018.06.006.","journal-title":"Chem Biol Interact"},{"issue":"1","key":"2895_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-022-00991-w","volume":"8","author":"Y Li","year":"2022","unstructured":"Li Y, Zeng P, Xiao J, Huang P, Liu P. Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy. Cell Death Discov. 2022;8(1):1\u201310. https:\/\/doi.org\/10.1038\/s41420-022-00991-w.","journal-title":"Cell Death Discov"},{"issue":"7","key":"2895_CR75","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41375-019-0700-9","volume":"34","author":"GA Horne","year":"2020","unstructured":"Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia. 2020;34(7):1775\u201386. https:\/\/doi.org\/10.1038\/s41375-019-0700-9.","journal-title":"Leukemia"},{"issue":"9","key":"2895_CR76","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1038\/bcj.2017.84","volume":"7","author":"M Matsushita","year":"2017","unstructured":"Matsushita M, Ozawa K, Suzuki T, Nakamura M, Nakano N, Kanchi S, Ichikawa D, Matsuki E, Sakurai M, Karigane D, Kasahara H, Tsukamoto N, Shimizu T, Mori T, Nakajima H, Okamoto S, Kawakami Y, Hattori Y. CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients. Blood Cancer J. 2017;7(9):e601\u2013e601. https:\/\/doi.org\/10.1038\/bcj.2017.84.","journal-title":"Blood Cancer J"},{"key":"2895_CR77","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41467-021-27928-8","volume":"13","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Takeda R, Fukushima T, Mikami K, Tsuchiya S, Tamura M, Adachi K, Umemoto T, Asada S, Watanabe N, Morishita S. Eliminating chronic myeloid leukemia stem cells by IRAK1\/4 inhibitors. Nat Commun. 2022;13:271. https:\/\/doi.org\/10.1038\/s41467-021-27928-8.","journal-title":"Nat Commun"},{"issue":"4","key":"2895_CR78","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3892\/ijmm.2020.4675","volume":"46","author":"Z Wuxiao","year":"2020","unstructured":"Wuxiao Z, Wang H, Su Q, Zhou H, Hu M, Tao S, Xu L, Chen Y, Hao X. MicroRNA-145 promotes the apoptosis of leukemic stem cells and enhances drug-resistant K562\/ADM cell sensitivity to adriamycin via the regulation of ABCE1. Int J Mol Med. 2020;46(4):1289\u2013300. https:\/\/doi.org\/10.3892\/ijmm.2020.4675.","journal-title":"Int J Mol Med"},{"key":"2895_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/418244a","author":"GJ Hannon","year":"2002","unstructured":"Hannon GJ. RNA interference. Nature. 2002. https:\/\/doi.org\/10.1038\/418244a.","journal-title":"Nature"},{"issue":"4","key":"2895_CR80","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrc1840","volume":"6","author":"A Esquela-Kerscher","year":"2006","unstructured":"Esquela-Kerscher A, Slack FJ. Oncomirs \u2014 microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259\u201369. https:\/\/doi.org\/10.1038\/nrc1840.","journal-title":"Nat Rev Cancer"},{"key":"2895_CR81","doi-asserted-by":"publisher","first-page":"1173970","DOI":"10.3389\/fonc.2023.1173970","volume":"13","author":"SC Wu","year":"2023","unstructured":"Wu SC, Lai SW, Lu XJ, Lai HF, Chen YG, Chen PH, Ho CL, Wu YY, Chiu YL. Profiling of miRNAs and their interfering targets in peripheral blood mononuclear cells from patients with chronic myeloid leukaemia. Front Oncol. 2023;13:1173970. https:\/\/doi.org\/10.3389\/fonc.2023.1173970.","journal-title":"Front Oncol"},{"key":"2895_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708765","author":"K Otmani","year":"2021","unstructured":"Otmani K, Lewalle P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.708765.","journal-title":"Front Oncol"},{"issue":"5","key":"2895_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065153","volume":"8","author":"R Zhou","year":"2013","unstructured":"Zhou R, Gong AY, Chen D, Miller RE, Eischeid AN, Chen XM. Histone deacetylases and NF-kB signaling coordinate expression of CX3CL1 in epithelial cells in response to microbial challenge by suppressing miR-424 and miR-503. PLoS ONE. 2013;8(5): e65153. https:\/\/doi.org\/10.1371\/journal.pone.0065153.","journal-title":"PLoS ONE"},{"issue":"16","key":"2895_CR84","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1093\/nar\/gkn522","volume":"36","author":"Q Liu","year":"2008","unstructured":"Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008;36(16):5391\u2013404. https:\/\/doi.org\/10.1093\/nar\/gkn522.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2895_CR85","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2015.02.031","volume":"360","author":"O Hershkovitz-Rokah","year":"2015","unstructured":"Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O, Granot G. Restoration of miR-424 suppresses BCR\u2013ABL activity and sensitizes CML cells to imatinib treatment. Cancer Lett. 2015;360(2):245\u201356. https:\/\/doi.org\/10.1016\/j.canlet.2015.02.031.","journal-title":"Cancer Lett"},{"issue":"6","key":"2895_CR86","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1128\/MCB.02005-06","volume":"27","author":"PS Linsley","year":"2007","unstructured":"Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR, Johnson JM, Cummins JM, Raymond CK, Dai H, Chau N. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol. 2007;27(6):2240\u201352. https:\/\/doi.org\/10.1128\/MCB.02005-06.","journal-title":"Mol Cell Biol"},{"issue":"50","key":"2895_CR87","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1038\/sj.onc.1206872","volume":"22","author":"MC Seminario","year":"2003","unstructured":"Seminario MC, Precht P, Wersto RP, Gorospe M, Wange RL. PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression. Oncogene. 2003;22(50):8195\u2013204. https:\/\/doi.org\/10.1038\/sj.onc.1206872.","journal-title":"Oncogene"},{"issue":"6","key":"2895_CR88","doi-asserted-by":"publisher","first-page":"8375","DOI":"10.1007\/s13277-015-4713-3","volume":"37","author":"Y Tian","year":"2016","unstructured":"Tian Y, Tian X, Han X, Chen Y, Song CY, Jiang WJ, Tian DL. ABCE1 plays an essential role in lung cancer progression and metastasis. Tumor Biol. 2016;37(6):8375\u201382. https:\/\/doi.org\/10.1007\/s13277-015-4713-3.","journal-title":"Tumor Biol"},{"issue":"3","key":"2895_CR89","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.critrevonc.2007.02.003","volume":"62","author":"SDPWM De Jonge-Peeters","year":"2007","unstructured":"De Jonge-Peeters SDPWM, Kuipers F, De Vries EGE, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol. 2007;62(3):214\u201326. https:\/\/doi.org\/10.1016\/j.critrevonc.2007.02.003.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2895_CR90","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ejca.2009.10.027","volume":"46","author":"R Hummel","year":"2010","unstructured":"Hummel R, Hussey DJ, Haier J. MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2010;46(2):298\u2013311. https:\/\/doi.org\/10.1016\/j.ejca.2009.10.027.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2895_CR91","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1124\/mol.110.066258","volume":"78","author":"EI Zimmerman","year":"2010","unstructured":"Zimmerman EI, Dollins CM, Crawford M, Grant S, Nana-Sinkam SP, Richards KL, Hammond SM, Graves LM, et al. Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Mol Pharmacol. 2010;78(5):811\u20137. https:\/\/doi.org\/10.1124\/mol.110.066258.","journal-title":"Mol Pharmacol"},{"issue":"5","key":"2895_CR92","doi-asserted-by":"publisher","first-page":"736","DOI":"10.4161\/cc.8.5.7870","volume":"8","author":"X Wang","year":"2009","unstructured":"Wang X, Gocek E, Liu CG, Studzinski GP. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle Georget Tex. 2009;8(5):736\u201341. https:\/\/doi.org\/10.4161\/cc.8.5.7870.","journal-title":"Cell Cycle Georget Tex"},{"issue":"5","key":"2895_CR93","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.cell.2010.01.007","volume":"140","author":"AM Eiring","year":"2010","unstructured":"Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010;140(5):652\u201365. https:\/\/doi.org\/10.1016\/j.cell.2010.01.007.","journal-title":"Cell"},{"issue":"1","key":"2895_CR94","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12943-016-0518-2","volume":"15","author":"CH Yeh","year":"2016","unstructured":"Yeh CH, Moles R, Nicot C. Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer. 2016;15(1):37. https:\/\/doi.org\/10.1186\/s12943-016-0518-2.","journal-title":"Mol Cancer"},{"key":"2895_CR95","doi-asserted-by":"publisher","first-page":"9666","DOI":"10.1038\/s41598-019-46132-9","volume":"9","author":"R Alves","year":"2019","unstructured":"Alves R, Gon\u00e7alves AC, Jorge J, Marques G, Lu\u00eds D, Ribeiro AB, Freitas-Tavares P, Oliveiros B, Almeida AM, Sarmento-Ribeiro AB. MicroRNA signature refine response prediction in CML. Sci Rep. 2019;9:9666. https:\/\/doi.org\/10.1038\/s41598-019-46132-9.","journal-title":"Sci Rep"},{"issue":"4","key":"2895_CR96","doi-asserted-by":"publisher","first-page":"8881","DOI":"10.1080\/21655979.2022.2056322","volume":"13","author":"X Zhu","year":"2022","unstructured":"Zhu X, Zhang J, Sun Y, Wang Y, Liu Q, Li P, Yu S, Liu N, Ye J, Ma D, Ji C. Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB. Bioengineered. 2022;13(4):8881\u201392. https:\/\/doi.org\/10.1080\/21655979.2022.2056322.","journal-title":"Bioengineered"},{"issue":"1","key":"2895_CR97","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/2162-3619-3-17","volume":"3","author":"L Xu","year":"2014","unstructured":"Xu L, Xu Y, Jing Z, Wang X, Zha X, Zeng C, Chen S, Yang L, Luo G, Li B, Li Y. Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia. Exp Hematol Oncol. 2014;3(1):17. https:\/\/doi.org\/10.1186\/2162-3619-3-17.","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"2895_CR98","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1080\/10428194.2018.1543875","volume":"60","author":"X Jiang","year":"2019","unstructured":"Jiang X, Cheng Y, Hu C, Zhang A, Ren Y, Xu X. MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5. Leuk Lymphoma. 2019;60(7):1709\u201320. https:\/\/doi.org\/10.1080\/10428194.2018.1543875.","journal-title":"Leuk Lymphoma"},{"key":"2895_CR99","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.gene.2017.05.030","volume":"626","author":"H Zhou","year":"2017","unstructured":"Zhou H, Li Y, Liu B, Shan Y, Li Y, Zhao L, Su Z, Jia L. Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression. Gene. 2017;626:106\u201318. https:\/\/doi.org\/10.1016\/j.gene.2017.05.030.","journal-title":"Gene"},{"issue":"12","key":"2895_CR100","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1158\/1541-7786.MCR-08-0167","volume":"6","author":"X Agirre","year":"2008","unstructured":"Agirre X, Jim\u00e9nez-Velasco A, San Jos\u00e9-En\u00e9riz E, Garate L, Bandr\u00e9s E, Cordeu L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A, P\u00e9rez-Roger I. Down-regulation of hsa-miR-10a in chronic myeloid Leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res. 2008;6(12):1830\u201340. https:\/\/doi.org\/10.1158\/1541-7786.MCR-08-0167.","journal-title":"Mol Cancer Res"},{"issue":"12","key":"2895_CR101","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3324\/haematol.2018.193086","volume":"103","author":"K Srutova","year":"2018","unstructured":"Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Polakova KM. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Haematologica. 2018;103(12):2016\u201325. https:\/\/doi.org\/10.3324\/haematol.2018.193086.","journal-title":"Haematologica"},{"key":"2895_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.616711","volume":"9","author":"J He","year":"2021","unstructured":"He J, Han Z, An Z, Li Y, Xie X, Zhou J, He S, Lv Y, He M, Qu H, Liu G, Li Y. The miR-203a regulatory network affects the proliferation of chronic myeloid leukemia K562 Cells. Front Cell Dev Biol. 2021;9: 616711. https:\/\/doi.org\/10.3389\/fcell.2021.616711.","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"2895_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-04209-2","volume":"12","author":"YY Wu","year":"2021","unstructured":"Wu YY, Lai HF, Huang TC, Chen YG, Ye RH, Chang PY, Lai SW, Chen YC, Lee CH, Liu WN, Dai MS, Chen JH, Ho CL, Chiu YL. Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance. Cell Death Dis. 2021;12(10):1\u201312. https:\/\/doi.org\/10.1038\/s41419-021-04209-2.","journal-title":"Cell Death Dis"},{"issue":"2","key":"2895_CR104","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.febslet.2010.12.027","volume":"585","author":"H Bai","year":"2011","unstructured":"Bai H, Xu R, Cao Z, Wei D, Wang C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 2011;585(2):402\u20138. https:\/\/doi.org\/10.1016\/j.febslet.2010.12.027.","journal-title":"FEBS Lett"},{"issue":"2","key":"2895_CR105","first-page":"447","volume":"8","author":"Q Li","year":"2016","unstructured":"Li Q, Wu Y, Zhang Y, Sun H, Lu Z, Du K, Fang S, Li W. miR-125b regulates cell progression in chronic myeloid leukemia via targeting BAK1. Am J Transl Res. 2016;8(2):447\u201359.","journal-title":"Am J Transl Res"},{"key":"2895_CR106","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1475-2867-13-110","volume":"13","author":"L Zhang","year":"2013","unstructured":"Zhang L, Li X, Ke Z, Huang L, Liang Y, Wu J, Zhang X, Chen Y, Zhang H, Luo X. MiR-99a may serve as a potential oncogene in pediatric myeloid leukemia. Cancer Cell Int. 2013;13:110. https:\/\/doi.org\/10.1186\/1475-2867-13-110.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"2895_CR107","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","volume":"109","author":"L Venturini","year":"2007","unstructured":"Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M, Scherr M. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007;109(10):4399\u2013405. https:\/\/doi.org\/10.1182\/blood-2006-09-045104.","journal-title":"Blood"},{"issue":"4","key":"2895_CR108","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.bbrc.2017.04.144","volume":"487","author":"Q Jia","year":"2017","unstructured":"Jia Q, Sun H, Xiao F, Sai Y, Li Q, Zhang X, Yang S, Wang H, Wang H, Yang Y, Wu CT. miR-17-92 promotes leukemogenesis in chronic myeloid leukemia via targeting A20 and activation of NF-\u03baB signaling. Biochem Biophys Res Commun. 2017;487(4):868\u201374. https:\/\/doi.org\/10.1016\/j.bbrc.2017.04.144.","journal-title":"Biochem Biophys Res Commun"},{"issue":"54","key":"2895_CR109","doi-asserted-by":"publisher","first-page":"92018","DOI":"10.18632\/oncotarget.21272","volume":"8","author":"M Kaehler","year":"2017","unstructured":"Kaehler M, Ruemenapp J, Gonnermann D, Nagel I, Bruhn O, Haenisch S, Ammerpohl O, Wesch D, Cascorbi I, Bruckmueller H. MicroRNA-212\/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells. Oncotarget. 2017;8(54):92018\u201331. https:\/\/doi.org\/10.18632\/oncotarget.21272.","journal-title":"Oncotarget"},{"key":"2895_CR110","doi-asserted-by":"publisher","first-page":"748","DOI":"10.17179\/excli2021-3404","volume":"20","author":"T Mahdloo","year":"2021","unstructured":"Mahdloo T, Sahami P, Ramezani R, Jafarinia M, Goudarzi H, Babashah S. Up-regulation of miR-155 potentiates CD34+ CML stem\/progenitor cells to escape from the growth-inhibitory effects of TGF-\u00df1 and BMP signaling. EXCLI J. 2021;20:748\u201363. https:\/\/doi.org\/10.17179\/excli2021-3404.","journal-title":"EXCLI J"},{"issue":"1","key":"2895_CR111","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41421-019-0092-z","volume":"5","author":"Y Liao","year":"2019","unstructured":"Liao Y, Liu N, Xia X, Guo Z, Li Y, Jiang L, Zhou R, Tang D, Huang H, Liu J. USP10 modulates the SKP2\/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia. Cell Discov. 2019;5(1):24. https:\/\/doi.org\/10.1038\/s41421-019-0092-z.","journal-title":"Cell Discov"},{"issue":"1","key":"2895_CR112","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41467-020-20259-0","volume":"12","author":"H Lei","year":"2021","unstructured":"Lei H, Xu HZ, Shan HZ, Liu M, Lu Y, Fang ZX, Jin J, Jing B, Xiao XH, Gao SM, Gao FH. Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem\/progenitor cells in chronic myelogenous leukemia. Nat Commun. 2021;12(1):51. https:\/\/doi.org\/10.1038\/s41467-020-20259-0.","journal-title":"Nat Commun"},{"issue":"1","key":"2895_CR113","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40364-021-00320-w","volume":"9","author":"H Lei","year":"2021","unstructured":"Lei H, Wang J, Hu J, Zhu Q, Wu Y. Deubiquitinases in hematological malignancies. Biomarker Res. 2021;9(1):66. https:\/\/doi.org\/10.1186\/s40364-021-00320-w.","journal-title":"Biomarker Res"},{"issue":"5","key":"2895_CR114","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41419-021-03732-6","volume":"12","author":"S Jiang","year":"2021","unstructured":"Jiang S, Wang X, He Y, Huang H, Cao B, Zhang Z, Liu J, Wang Q, Huang Z, Mao X. Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis. Cell Death Dis. 2021;12(5):456. https:\/\/doi.org\/10.1038\/s41419-021-03732-6.","journal-title":"Cell Death Dis"},{"key":"2895_CR115","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3103\/S0095452716050029","volume":"50","author":"SV Antonenko","year":"2016","unstructured":"Antonenko SV, Gurianov DS, Telegeev GD. Colocalization of USP1 and PH domain of Bcr-Abl oncoprotein in terms of chronic myeloid leukemia cell rearrangements. Cytol Genet. 2016;50:352\u20136. https:\/\/doi.org\/10.3103\/S0095452716050029.","journal-title":"Cytol Genet"},{"issue":"2","key":"2895_CR116","doi-asserted-by":"publisher","first-page":"109","DOI":"10.32471\/exp-oncology.2312-8852.vol-42-no-2.14533","volume":"42","author":"SV Antonenko","year":"2020","unstructured":"Antonenko SV, Telegeev GD. Inhibition of USP1, a new partner of Bcr-Abl, results in decrease of Bcr-Abl level in K562 cells. Exp Oncol. 2020;42(2):109\u201314. https:\/\/doi.org\/10.32471\/exp-oncology.2312-8852.vol-42-no-2.14533.","journal-title":"Exp Oncol"},{"issue":"2","key":"2895_CR117","doi-asserted-by":"publisher","first-page":"219","DOI":"10.18388\/abp.2020_6636","volume":"70","author":"S Antonenko","year":"2023","unstructured":"Antonenko S, Zavelevich M, Telegeev G. The role of USP1 deubiquitinase in the pathogenesis and therapy of cancer. Acta Biochim Pol. 2023;70(2):219\u201331. https:\/\/doi.org\/10.18388\/abp.2020_6636.","journal-title":"Acta Biochim Pol"},{"issue":"42","key":"2895_CR118","doi-asserted-by":"publisher","first-page":"44061","DOI":"10.18632\/oncotarget.6392","volume":"6","author":"S Valletta","year":"2015","unstructured":"Valletta S, Dolatshad H, Bartenstein M, Yip BH, Bello E, Gordon S, Yu Y, Shaw J, Roy S, Scifo L, Schuh A. ASXL1 mutation correction by CRISPR\/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts. Oncotarget. 2015;6(42):44061. https:\/\/doi.org\/10.18632\/oncotarget.6392.","journal-title":"Oncotarget"},{"issue":"16","key":"2895_CR119","doi-asserted-by":"publisher","first-page":"26027","DOI":"10.18632\/oncotarget.15215","volume":"8","author":"I Garc\u00eda-Tu\u00f1\u00f3n","year":"2017","unstructured":"Garc\u00eda-Tu\u00f1\u00f3n I, Hern\u00e1ndez-S\u00e1nchez M, Ordo\u00f1ez JL, Alonso-P\u00e9rez V, \u00c1lamo-Quijada M, Benito R, Guerrero C, Hern\u00e1ndez-Rivas JM, S\u00e1nchez-Mart\u00edn M. The CRISPR\/Cas9 system efficiently reverts the tumorigenic ability of BCR\/ABL in vitro and in a xenograft model of chronic myeloid leukemia. Oncotarget. 2017;8(16):26027. https:\/\/doi.org\/10.18632\/oncotarget.15215.","journal-title":"Oncotarget"},{"issue":"12","key":"2895_CR120","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.3390\/ijms23126386","volume":"23","author":"E Vuelta","year":"2022","unstructured":"Vuelta E, Ordo\u00f1ez JL, Sanz DJ, Ballesteros S, Hern\u00e1ndez-Rivas JM, M\u00e9ndez-S\u00e1nchez L, S\u00e1nchez-Mart\u00edn M, Garc\u00eda-Tu\u00f1\u00f3n I. CRISPR\/Cas9-directed gene trap constitutes a selection system for corrected BCR\/ABL leukemic cells in cML. Int J Mol Sci. 2022;23(12):6386. https:\/\/doi.org\/10.3390\/ijms23126386.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2895_CR121","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1038\/s41467-022-31386-1","volume":"13","author":"D Lain\u0161\u010dek","year":"2022","unstructured":"Lain\u0161\u010dek D, Forstneri\u010d V, Mikoli\u010d V, Malen\u0161ek \u0160, Pe\u010dan P, Ben\u010dina M, Sever M, Podgornik H, Jerala R. Coiled-coil heterodimer-based recruitment of an exonuclease to CRISPR\/Cas for enhanced gene editing. Nat Commun. 2022;13(1):3604. https:\/\/doi.org\/10.1038\/s41467-022-31386-1.","journal-title":"Nat Commun"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02895-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02895-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02895-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T06:03:23Z","timestamp":1753941803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02895-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":121,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2895"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02895-y","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This review article does not need ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Formal consent is not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"344"}}